AKELA Pharma Inc. - Financial and Strategic Analysis Review

AKELA Pharma Inc. - Financial and Strategic Analysis Review

Summary

Global Markets Direct’s “AKELA Pharma Inc. - Financial and Strategic Analysis Review” is an in-depth business, strategic and financial analysis of AKELA Pharma Inc. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.

Akela Pharma Inc., (Akela) is an integrated product development company focused on developing drug delivery technologies and therapeutics for the pain market. It also provides research and development services including specialty drug manufacturing, product development & testing, analytical method development and patent litigation support services. Taifuno is the company’s Inhalation Drug Delivery Platform. The company's lead product, Fentanyl TAIFUN is under development is for the treatment of breakthrough cancer pain. It is a fast-acting fentanyl formulation, delivered using the company’s approved TAIFUN dry powder inhaler platform.

Recent Developments

Nov 04, 2009: Akela Enhances Its Manufacturing Capabilities With Spray Drying Technology
Nov 04, 2009: AKELA Adds Spray Drying Technology To Bioavailability Enhancement Solutions
Aug 17, 2009: AKELA Pharma Reports Total Revenues Of $4 Million In Q2 2009

Scope

• Provides key company information for business intelligence needs
• The company’s strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered.
• The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted.
• The report contains critical company information - business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
• The report provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
• Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Reasons to buy

• A quick “one-stop-shop” to understand the company.
• Enhance business/sales activities by understanding customers’ businesses better.
• Get detailed information and financial & strategic analysis on companies operating in your industry.
• Identify prospective partners and suppliers - with key data on their businesses and locations.
• Capitalize on competitors’ weaknesses and target the market opportunities available to them.
• Compare your company’s financial trends with those of your peers / competitors.
• Scout for potential acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.